The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
Publication number:
EP3209295
WO Application Number:
US2015056273
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP15852340.7
WO Publication Number:
WO2016064759
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
United States of America (US)
Publications:
Dates
Filing date:
19/10/2015
Grant date:
09/12/2020
EP Publication Date:
30/08/2017
WO Publication Date:
28/04/2016
Claims Translations Received Date:
Claims Translation B1 Received Date:
19/02/2021
Claims Translation B2 Received Date:
12/02/2024
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
09/12/2020
EP B1 Publication Date:
09/12/2020
EP B2 Publication Date:
06/12/2023
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
18/10/2035
Lapsed By Expiration Date:
Patent Validated Date:
21/02/2024
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:
Applicant/holder
From:
09/12/2020
Name:
Oyster Point Pharma, Inc.
Address:
202 Carnegie Center, Suite 109, Princeton, New Jersey 08540, United States of America (US)